There’s a new commander in charge at BVI. Jim Hollingshead has been named president and CEO to succeed Shervin Korangy, who will continue to serve as an advisor to the company and begin a new role as senior advisor to TPG Capital.  

“I want to thank the entire BVI team for their partnership in transforming the company into the platform it is today,” Korangy stated. “I am proud of the breadth of portfolio and pipeline we have built, creating a challenger to the long-standing status quo in the industry. I look forward to continuing to support the company as it builds on its strong roadmap under Jim’s leadership.”

Hollingshead has more than 20 years of experience leading and growing medical device and life sciences companies. He most recently was CEO of insulin delivery solutions provider Insulet. During Hollingshead’s tenure, the company furthered its market leadership through expanded product offerings, including launching the industry’s first patch pump automated insulin delivery system. Previously, Hollingshead spent 12 years at ResMed, where he last served as president for the company’s sleep and respiratory care business. 

“I have long been inspired by the role that technology innovation can play in improving patient experience and outcomes,” Hollingshead said. “BVI is transforming vision care through a simple and effective mission to deliver trusted solutions tailored to the needs of physicians and their patients. It’s a privilege to join the BVI team as we build on the company’s strong momentum and launch multiple new, platforms.” 

Over the past several years, BVI has expanded its purpose-built portfolio. It claims to have developed one of the most robust product pipelines in the industry and now delivers a full procedural solution for the cataract and retina surgical market. The company expanded its intraocular lens (IOL) platform to meet growing global demand and introduced new product lines such as SERENITY and SERENITY Toric, which deliver far and intermediate range vision. In 2025, BVI received U.S. Food and Drug Administration (FDA) approval for its FINEVISION HP trifocal IOL, bringing premium IOL solutions to U.S. patients. The company also debuted its FDA-cleared Leos glaucoma system, marking a significant advancement in glaucoma care, and unveiled Virtuoso, a dual-function phaco-vitrectomy platform for cataract and vitreoretinal procedures.

“Jim’s strategic vision, insight, and track record of innovation and transformation in the medical device industry make him an excellent fit for BVI as the company continues to advance its market leadership and scale its impact globally,” BVI Chairman Ron Labrum said. “We want to recognize Shervin for his leadership as BVI developed one of the most innovative product portfolios in the industry and know the team will continue to benefit from his expertise.”

BVI is a diversified global ophthalmic device company delivering solutions and innovation for advancing eye surgery and improving patients’ vision. With nine decades of developing products and solutions, BVI partners with ophthalmic surgeons to improve patients’ vision. The organization supports surgical teams in more than 90 countries worldwide, either directly or through a network of distributors.